IGC Pharma (NYSEMKT:IGC) Shares Down 8.9% – What’s Next?

Posted by ABMN Staff on Dec 6th, 2025

IGC Pharma, Inc. (NYSEMKT:IGC – Get Free Report)’s stock price dropped 8.9% on Friday . The stock traded as low as $0.3224 and last traded at $0.2970. Approximately 214,616 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 913,992 shares. The stock had previously closed at $0.3261.

Analyst Ratings Changes

Separately, Zacks Research cut shares of IGC Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.88.

View Our Latest Research Report on IGC Pharma

IGC Pharma Trading Down 8.9%

The company has a market cap of $27.58 million, a price-to-earnings ratio of -2.70 and a beta of 0.24. The business has a fifty day simple moving average of $0.37 and a 200 day simple moving average of $0.36. The company has a quick ratio of 0.98, a current ratio of 1.15 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IGC Pharma stock. Virtu Financial LLC raised its stake in IGC Pharma, Inc. (NYSEMKT:IGC – Free Report) by 91.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,546 shares of the company’s stock after buying an additional 42,654 shares during the period. Virtu Financial LLC owned approximately 0.10% of IGC Pharma worth $37,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.87% of the company’s stock.

About IGC Pharma

(Get Free Report)

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.